Rare Autosomal Recessive Cardiac Valvular Form of Ehlers-Danlos Syndrome Results from Mutations in the COL1A2 Gene That Activate the Nonsense-Mediated RNA Decay Pathway  by Schwarze, Ulrike et al.
Am. J. Hum. Genet. 74:917–930, 2004
917
Rare Autosomal Recessive Cardiac Valvular Form of Ehlers-Danlos
Syndrome Results from Mutations in the COL1A2 Gene That Activate
the Nonsense-Mediated RNA Decay Pathway
Ulrike Schwarze,1 Ryu-Ichiro Hata,3 Victor A. McKusick,4 Hiroshi Shinkai,5
H. Eugene Hoyme,6 Reed E. Pyeritz,7 and Peter H. Byers1,2
Departments of 1Pathology and 2Medicine, University of Washington, Seattle; 3Department of Biochemistry and Molecular Biology
and Research Center of Advanced Technology for Craniomandibular Function, Kanagawa Dental College, Yokosuka, Japan;
4McKusick-Nathans Institute of Genetic Medicine, Baltimore; 5Department of Dermatology, Chiba University School of Medicine, Chiba,
Japan; 6Department of Pediatrics, Stanford University School of Medicine, Stanford; and 7Department of Medicine, University
of Pennsylvania, Philadelphia
Splice site mutations in the COL1A2 gene of type I collagen can give rise to forms of Ehlers-Danlos syndrome
(EDS) because of partial or complete skipping of exon 6, as well as to mild, moderate, or lethal forms of osteogenesis
imperfecta as a consequence of skipping of other exons. We identiﬁed three unrelated individuals with a rare
recessively inherited form of EDS (characterized by joint hypermobility, skin hyperextensibility, and cardiac valvular
defects); in two of them, COL1A2 messenger RNA (mRNA) instability results from compound heterozygosity for
splice site mutations in the COL1A2 gene, and, in the third, it results from homozygosity for a nonsense codon.
The splice site mutations led to use of cryptic splice donor sites, creation of a downstream premature termination
codon, and extremely unstable mRNA. In the wild-type allele, the two introns (IVS11 and IVS24) in which these
mutations occurred were usually spliced slowly in relation to their respective immediate upstream introns. In the
mutant alleles, the upstream intron was removed, so that exon skipping could not occur. In the context of the
mutation in IVS24, computer-generated folding of a short stretch of mRNA surrounding the mutation site dem-
onstrated realignment of the relationships between the donor and acceptor sites that could facilitate use of a cryptic
donor site. These ﬁndings suggest that the order of intron removal is an important variable in prediction of mutation
outcome at splice sites and that folding of the nascent mRNA could be one element that contributes to determination
of order of splicing. The complete absence of proa2(I) chains has the surprising effect of producing cardiac valvular
disease without bone involvement.
Introduction
Classic Ehlers-Danlos syndrome (EDS) (MIM 130000
and MIM 130010), also known as “EDS types I and
II,” is generally a dominantly inherited condition char-
acterized by joint laxity, skin hyperextensibility and fri-
ability, and abnormal scar formation. It usually results
from mutations in the COL5A1 gene (Nicholls et al.
1996; Wenstrup et al. 1996, 2000; De Paepe et al. 1997;
Giunta and Steinmann 2000; Schwarze et al. 2000;
Bouma et al. 2001). Mutations in the COL5A2 gene
(Michalickova et al. 1998; Richards et al. 1998), the
tenascin X gene (TNXB [MIM 606408]) (Burch et al.
1997; Schalkwijk et al. 2001), and the gene that encodes
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the proa1(I) chains of type I procollagen (COL1A1)
(Nuytinck et al. 2000) have also been implicated.
A recessively inherited form of EDS characterized by
the changes of classic EDS results from failure to syn-
thesize proa2(I) chains of type I procollagen (MIM
120160) (Sasaki et al. 1987; Hata et al. 1988). In ad-
dition to the usual skin and joint involvement, individ-
uals with this form of EDS appear to be at increased
risk for cardiac valvular dysfunction. In one instance in
which homozygosity for aCOL1A2 splice site mutation
(IVS462TrC) was identiﬁed (Nicholls et al. 2001),
although no proa2(I) chains could be seen, the patient
had a mixed phenotype that included elements of os-
teogenesis imperfecta (OI)—skull and long-bone frac-
tures—but there was no cardiovascular system involve-
ment by age 9 years.
We have now identiﬁed causative mutations in the
COL1A2 gene in three unrelated individuals whose skin
ﬁbroblasts failed to make proa2(I) chains and who had
EDS and cardiovascular involvement but no suggestion
of OI. Each individual either was a compound hetero-
zygote for two splice mutations that led to mRNA in-
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stability in the spliced product or had a homozygous
nonsense mutation.
Most splice site mutations in the COL1A2 gene iden-
tiﬁed to date produce exon skipping and result in an
OI phenotype (Byers and Cole 2002). In contrast, the
splice site mutations in the form of EDS we describe
here led to use of cryptic splice sites, creation of pre-
mature termination codons (PTCs), and unstable m-
RNAs. A nonsense mutation that introduces a PTC has
the same phenotypic effect and alters mRNA processing
in an identical fashion. The outcomes of the splice site
mutations could be predicted by the local order of intron
removal and the presence of available cryptic splice
sites. These ﬁndings suggest that the order of intron
removal is a critical factor in the determination of out-
come of splice site mutations, which then mediates the
clinical phenotypes. Further, homozygosity or com-
pound heterozygosity for COL1A2 null mutations ap-
pears to deﬁne a subset of individuals with EDS who
have a cardiac valvular phenotype.
Patients, Material, and Methods
Patients
The three individuals described here received diag-
noses, on clinical grounds, of the classic form of EDS
(types I and II) and were studied further when it was
noted that their cultured ﬁbroblasts appeared to syn-
thesize no proa2(I) chains of type I procollagen. All bi-
opsies were performed after appropriate consent was
received.
Patient 1 (P1) was a 45-year-old man who received
the diagnosis of EDS type II because of recurrent shoul-
der dislocations since childhood, small-joint hypermo-
bility, pectus excavatum, muscle and tendon tears, bi-
lateral inguinal hernias, small scars under the chin and
on the forehead, atrophic scars over the knees and shins,
easy bruisability, and generally hyperextensible and thin
skin. He was myopic and had bilateral astigmatism. For
many years, he was known to have a systolic murmur,
and a recent echocardiogram demonstrated anterior mi-
tral leaﬂet prolapse, resulting in severe mitral regurgi-
tation with systolic ﬂow reversal in the left upper pul-
monary vein. The left atrium and the left ventricle were
dilated, there was mild ventricular hypertrophy, and
there was moderate aortic insufﬁciency. The aortic root
diameter was 36 mm (normal range 20–37 mm). Fol-
lowing episodes of arrhythmias and atrial ﬁbrillation, he
underwent mitral and aortic valve replacement surgery.
The procedure itself was uneventful; however, once the
prosthetic valves were placed, ﬁrst the mitral annulus
(not the prosthetic valve) dehisced from the ventricle,
then the aortic valve separated from the atrioventricular
groove, and ﬁnally there was massive leakage through
the left ventricular myocardium with disintegration of
the entire left ventricle, from which the patient died.
The subject’s mother and his only child havemild joint
laxity without dislocations. Collagen ﬁbrils in skin were
slightly larger than normal and more ovoid than in con-
trol individuals but did not contain the characteristic
aggregate ﬁbrils seen in skin from individuals with EDS
type I (Vogel et al. 1979).
Patient 2 (P2) is a woman with EDS type II, described
elsewhere (Kojima et al. 1988), who is now aged 65
years. She was reported to have soft skin, moderate skin
hyperextensibility, joint hypermobility (especially of the
ﬁngers and hands), easy bruisability, and atrophic scar
formation. At age 38 years, she sought evaluation be-
cause of palpitations, a pansystolic murmur, dyspnea,
and fatigue, which led to the diagnosis of mitral valve
insufﬁciency. Mitral valve replacement surgery was
performed, and the postoperative course was largely
uneventful.
Collagen ﬁbrils in skin showed more variation in di-
ameter than normal, but composite ﬁbrils were not de-
tected (Kojima et al. 1988).
P2 has no history of fractures. Her skin hyperexten-
sibility and joint hypermobility have remained unchan-
ged. She has no children.
Patient 3 (P3) is a 30-year-old man whose phenotyp-
ically normal parents are second cousins. He was born
with bilateral inguinal hernias and, as a teenager, un-
derwent surgical repair of pes planus and calcaneoval-
gus. He has always had signiﬁcant large- and small-joint
hypermobility, with bilateral genu recurvatum. His skin
is soft and hyperextensible, with striae at the lateral as-
pect of the abdomen. He bruises easily, and his wound
healing is delayed. He had a large secundum-type atrial
septal defect, mitral valve prolapse with signiﬁcant mi-
tral regurgitation, and severe aortic valve regurgitation.
His aortic root diameter at age 29 years was 36 mm, at
the upper limit of normal. He developed marked left
ventricular enlargement and had his aortic and mitral
valves replaced with prosthetic valves, with no surgical
complications. Of note, the femoral artery and vein per-
forated in the course of preoperative diagnostic cardiac
catheterization, and the cardiac surgeon described his
tissues as extremely soft. P3 has a 27-year-old brother,
with hyperextensible small joints and soft but not sig-
niﬁcantly hyperextensible skin, who required aortic
valve replacement at age 25 years because of aortic in-
sufﬁciency. Their parents are reported to have no evi-
dence of valvular heart disease.
Cell Culture and Analysis of Collagenous Proteins
Dermal ﬁbroblasts were obtained from explants of
skin biopsies from the three individuals. Growth and
maintenance of those and control cell strains, radiola-
Schwarze et al.: COL1A2 Null Mutations and Splice Order 919
Figure 1 SDS-PAGE of radiolabeled procollagens and collagens.
Procollagens were analyzed under reducing conditions, whereas col-
lagens were separated without prior reduction. In P3, proa2(I) and
a2(I) chains were absent, and some overmodiﬁcation due to the for-
mation of proa1(I) homotrimers was visible as a slight delay in elec-
trophoretic mobility of the a1(I) chains. Cells from the other two
patients behaved in the same manner. FN p ﬁbronectin.
Figure 2 Ampliﬁcation of COL1A2 coding sequence. A, Am-
pliﬁcation products extending from exon 5 to 22 and from exon 20
to 35 in a control individual (C) and in P1. In P1, in addition to the
normal-size band, there were a slower-than-normal migrating band
(ins) and a heteroduplex band (H1) in the x5rx22 product and a pair
of heteroduplex bands (H2) in the x20rx35 product. B, Very low
abundance of mutant transcripts in P1. The same PCRs were per-
formed as for panel A, but when a C/P1 cDNA-mix was used as PCR
template, only normal transcripts from the control individual were
visible, indicating that transcripts from both COL1A2 alleles in P1
were of very low abundance.C,Ampliﬁcation products extending from
exon 20 to 35 in the control individual and P2. The pair of hetero-
duplex bands in P2 (H) looked identical to that seen in P1. D, Am-
pliﬁcation products extending from exon 1 to 8 in the control indi-
vidual and P2. Owing to poor P2 cell growth, the RNA preparation
was of low concentration, and, after 35 PCR cycles, there was hardly
any product visible. It required 39 cycles to visualize the two products,
one of normal size and a second one of slower mobility (ins). M p
l # PstI (molecular size marker).
beling of collagenous proteins, and analysis of proa
chains and a chains with SDS-PAGE were performed as
described elsewhere (Bonadio et al. 1985).
Preparation of cDNA and Genomic DNA
Total cellular RNA and genomic DNAwere extracted,
using the RNeasy Mini Kit (Qiagen) and QIAamp DNA
Mini Kit (Qiagen), respectively, from cultured dermal
ﬁbroblasts of the patients and a control individual. In
addition, nuclear RNA was prepared from cultured ﬁ-
broblasts of P1 and a control cell strain by use of rea-
gents from the RNeasy Mini Kit. In brief, conﬂuent 100-
mm plates were rinsed with ice cold 1X PBS before the
addition of 500 ml of ice-cold RLN-buffer (50 mM Tris-
Cl, pH 8.0; 140 mM NaCl; 1.5 mM MgCl2; 0.5% [v/
v] Nonidet P-40). The cells were gently detached with
a sterile cell scraper, were transferred to a microfuge
tube, and were incubated on ice for 5 min to lyse the
plasma membrane. Following centrifugation (5 min;
; 4C), there was a soft, translucent pellet that700# g
contained the nuclei and the supernatant that contained
the cytoplasmic fraction. The latter was carefully trans-
ferred to a new tube, 600 ml of Qiagen’s RLT-buffer with
b-mercaptoethanol (b-ME) was added, and the mixture
was stored at 80C for later isolation of the cytoplas-
mic RNA, according to the manufacturer protocol. To
remove residual cytoplasmic RNA from the nuclear frac-
tion, 300 ml of RLN-buffer was added, and, after cen-
trifugation (3 min; ; 4C), the supernatant was700# g
discarded. Then 700 ml of RLT-buffer with b-ME was
added, and the genomic DNA was sheared by repeated
passage through a 22G needle. After centrifugation (5
min; ; 20C), the supernatant was transferred21,000# g
to a new microfuge tube, 700 ml of 70% ethanol was
added, and the RNA was isolated using the RNeasy
column, as described by the manufacturer. TheRNAwas
eluted from the column in 70 ml of DEPC-water.
cDNA was synthesized by priming total RNA with
random hexamers in the presence of Superscript II re-
verse transcriptase (Invitrogen) or priming nuclear RNA
after treatment with DNase I (Roche) for 20min at 37C,
with the incubation buffer recommended by the manu-
facturer. To check for residual genomic DNA in the RNA
preparation, a control PCR was done without prior re-
verse transcription.
Ampliﬁcation of the COL1A2 Coding Sequence
and Sequence Determination of Aberrant Products
TheCOL1A2 cDNAwas ampliﬁed in ﬁve overlapping
fragments, with primer sets listed in table A (online
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Figure 3 Schematic depiction of the “null” mutations identiﬁed in both COL1A2 alleles in each of the three patients. Asterisks (*) indicate
the locations of in-frame PTCs. A, In P1, one allele, IVS115GrA, resulted in use of a cryptic donor site 61 nt downstream (underlined) and
inclusion of the most-5′ 60 nt of intron 11. The mature mRNA contained an in-frame PTC. In the other allele, IVS241GrC resulted in use
of a cryptic donor site 8 nt upstream in exon 24 (underlined), truncation of exon 24 by 8 nt, and a reading-frameshift with introduction of a
PTC in exon 26. B, In P2, one allele harbored an ArG transition in intron 1 (IVS1717ArG) that activated a cryptic exon and led to inclusion
of a 105-nt exon that contained four in-frame PTCs. In the other allele, IVS241GrA resulted, as in P1, in use of a cryptic donor site 8 nt
upstream in exon 24 (underlined), truncation of exon 24 by 8 nt, and a reading-frameshift with introduction of a PTC in exon 26. C, P3 was
homozygous for a point mutation (c.3601GrT) in exon 50 that resulted in substitution of a codon for glutamic acid by a nonsense codon
(E1201X).
only), and the fragments were separated on 6% non-
denaturing polyacrylamide gels. If extra bands (hetero-
duplex and/or homoduplex bands) were present in
cDNA ampliﬁcation products, they were excised from
the gel and reampliﬁed, and the sequence of the ream-
pliﬁcation products was determined by ABI PRISM
BigDye Terminator cycle sequencing reaction on an ABI
PRISM 310 Genetic Analyzer (Perkin-Elmer Applied
Biosystems). If no aberrant ampliﬁcation products were
detectable, all ﬁve cDNA fragments were sequenced di-
rectly. In instances of altered pre-mRNA splicing, ge-
nomic DNA was ampliﬁed using the primer sets listed
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Figure 4 Relationship between the cryptic exon in COL1A2 intron 1 and a remnant of a large exon 2 in the same domain. In one allele
from P2, an ArG transition at position 717 in intron 1 (indicated by an asterisk [*]) creates a new donor site and allows inclusion of the newly
deﬁned exon (gray box) in the transcript. Exon 2 in the COL1A2 gene is very small (11 nt), compared with 195 nt in the COL1A1 gene and
203 nt in the COL3A1 gene. This difference accounts for most of the size difference in the N-terminal propeptide. Comparison of the COL1A1
exon 2 with the sequence of intron 1 of COL1A2 revealed a region of 46% identity over a 207-nt interval (977–1183) of the intron, downstream
from the activated cryptic exon. This suggests that the activated exon, which has no signiﬁcant identity with the COL1A1 exon 2, is not the
remnant of the lost exon 2 sequences.
in table B (online only), and the products were sequenced
directly to identify the causative mutation.
For P1, an additional primer pair for ampliﬁcation of
cDNAwas used to verify that themutations were located
on separate COL1A2 alleles. The sense primer (5′-CTT-
TACTCAGAAGAGAGAAAATGCCTAT-3′) was de-
rived from the retained portion of intron 11 sequence,
and the antisense primer (5′-CAGGCTCTCCTCTTGC-
TCCAG-3′) from exon 25.
Determination of the Order of Intron Removal in Two
Regions of the COL1A2 Gene
To determine the order of intron removal between
exon 10 and intron 12 and between exons 23 and 26
of COL1A2 pre-mRNA, the splicing intermediates in the
nucleus were analyzed by a PCR strategy described by
Kessler and colleagues (1993) and detailed by Schwarze
and colleagues (1999). Nucleotide sequences of the prim-
ers used are listed in table C (online only).
RNA Secondary Structure Prediction
COL1A2 sequences were folded with the RNA-fold-
ing program mfold, version 3.1 (Zuker 2003). The se-
quences contained exons 23–26, with introns 24 and 25
for the normal control, and exons 23–26, with intron
24 for the normal control, as well as for P1 and P2, in
whom the intron 24 splice donor site was disrupted by
a point mutation (see the “Results” section).
Results
Mutation Identiﬁcation and Characterization
The cells from P1, P2, and P3 synthesized no detect-
able amounts of the proa2(I) chain of type I procollagen
(ﬁg. 1). Ampliﬁcation of COL1A2 cDNA derived from
total cellular RNA yielded products detectable by PAGE
for all three subjects, after 35 cycles (P1 and P3) or 39
cycles (P2) of PCR. In P1, the cDNA fragment ampliﬁed
by primers in exons 5 and 22 showed, in addition to
the product of normal size, a smaller amount of a more
slowly migrating product and a heteroduplex band (ﬁg.
2A). The overlapping fragment ampliﬁed by primers in
exons 20 and 35 revealed a pair of heteroduplex bands
(ﬁg. 2A) and the normally sized fragment. This latter
abnormality was also seen in P2 (ﬁg. 2C) with the same
primer pair; in addition, the fragment ampliﬁed by prim-
ers in exon 1 and 8 from P2 contained an extra band
of slower-than-normal mobility (ﬁg. 2D). In P3, all ﬁve
overlapping cDNA fragments were of the expected
size, without evidence of heteroduplex formation (not
shown).
The amount of the transcripts from the mutant alleles
was extremely low, as demonstrated when approxi-
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Figure 5 Order of intron removal between exon 10 and intron 12. Nuclear RNA was prepared from cultured ﬁbroblasts after deﬁned
intervals of exposure to Actinomycin D, was treated with RNase-free DNase, was reverse transcribed, and was ampliﬁed with intron-exon
primer pairs (the sense primer of which was radioactively end-labeled), and the products were separated by PAGE. The splicing intermediates,
visualized by autoradiography, are schematically depicted in the center. A, Control Individual, The majority of the ampliﬁed product at 0 min
contained introns 10 and 11; the less abundant product contained only intron 10. There was some transfer of the label from the large to the
small fragment between 0 min and 10 min, but most of the label from the large fragment was lost without transfer. These ﬁndings are consistent
with parallel pathways in which either intron 10 or intron 11 is removed ﬁrst (ﬁg. 6). P1, There is accumulation of the product that contains
both intron 10 and intron 11, largely from the mutant allele. Use of a cryptic donor site in intron 11 generated a new splice intermediate, with
retention of the ﬁrst 60 nt (thick black line) in a minority of intron 10–containing transcripts. B, Control Individual, Intron 12 was removed
slowly relative to intron 11. P1, There was delay of mutant allele processing, but processing of the normal allele was parallel to that in the
control individual. Exon 11 of the mutant allele was “redeﬁned” using the intronic cryptic donor site and retention of 60 nt of intron 11. The
spliced mutant transcript was retained in the nucleus for a longer period than the normally spliced transcript. Hp heteroduplex formed between
the normally spliced product and the product that retained part of intron 11. C, Control Individual, Removal of intron 12 was preceded by
removal of introns 10 and 11. P1, The processing of the mutant allele was delayed, removal of introns 10 and 11 was slower than in the
control individual, and the ﬁnal product of the mutant allele contained the redeﬁned exon 11 (ﬁg. 6). Arrows indicate the annealing sites of
the ampliﬁcation primers (table C [online only]). G indicates a PCR control with genomic DNA in each panel. A dagger (†) indicates the
contribution in P1 of both alleles to the detected product; an asterisk (*) tags products derived from only the mutant allele (IVS115GrA).
mately equal amounts of control cDNA and P1 cDNA
were mixed, ampliﬁed with the relevant primers, and the
products examined by PAGE. None of the heterodu-
plexes seen when P1 cDNA alone was used as a substrate
were visible (ﬁg. 2B).
Compound heterozygosity in P1.—The larger frag-
ment derived from the exon 5–22 domain in P1 (ﬁg. 2A
[“ins”]) included the most-5′ 60 nt of intron 11 in the
mature mRNA. The included sequence contained aGrA
transition at the 5 position of the intron 11 splice-
donor site (IVS115GrA). This mutation was hetero-
zygous in genomic DNA. In the product of that allele,
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Figure 6 Pathways of removal of introns 10, 11, and 12 from the normal and mutant COL1A2 transcripts. Normal Allele, Two pathways
were present, a dominant one in which intron 10 was excised prior to removal of introns 11 and 12 (encircled 1), and a second in which
removal of intron 11 preceded that of introns 10 and 12 (encircled 2). Intron 12 was removed last. Mutant Allele 1, There was delay in removal
of introns 10 and 11. The intermediate was then generally processed by removal of intron 10, although in some but fewer transcripts, exon
11 was redeﬁned using the cryptic intron 11 donor site prior to removal of intron 10 (shown in ﬁg. 5A). Intron sizes are shown in the unspliced
normal transcript. An asterisk (*) indicates the site of the mutation. The width of the arrows reﬂects the amount of product derived from the
respective branch of the pathway.
a cryptic donor site 61 nt downstream in intron 11 (ﬁg.
3A [Allele 1]) was used. The retained portion of intron
11 contained an in-frame PTC (TAA) that renders tran-
scripts from that allele unstable due to nonsense-medi-
ated mRNA decay (Maquat and Carmichael 2001).
Reampliﬁcation of the excised heteroduplex band seen
in the same fragment (ﬁg. 2A [H1]) reproduced the prod-
uct pattern observed after the initial PCR (not shown),
and there was no evidence of a skipped-exon product.
Sequencing of the excised and reampliﬁed heterodu-
plex bands seen in P1 in the fragment extending from
exon 20 to 35 (ﬁg. 2A [H2]) revealed heterozygosity for
truncation of exon 24 by 8 nt. Heterozygosity for a GrC
transversion at the 1 position of the intron 24 splice
donor site (IVS241GrC) led to use of a cryptic donor
site 8 nt upstream in exon 24 (ﬁg. 3A [Allele 2]). The
deletion of 8 nt caused a reading-frameshift and intro-
duced a PTC (TGA) 101 nt downstream in exon 26. To
verify that the two splice donor site mutations were lo-
cated on separate COL1A2 alleles, cDNA was ampliﬁed
with a sense primer that annealed to the retained portion
of intron 11 and with an antisense primer in exon 25
(see the “Material and Methods” section). The presence
of an intact exon 24 in this product proved that the
mutations arose on separate alleles.
Compound heterozygosity in P2.—The abnormal
product seen in the fragment extending from exon 1 to
exon 8 (ﬁg. 2D [ins]) was caused by retention of 105 nt
from within intron 1 in one COL1A2 allele comprising
nt 612–716 of the intron (ﬁg. 3B [Allele 1]). This in-
sertion represents a cryptic exon that was ﬂanked by a
canonical splice acceptor site (cag), with an intact po-
lypyrimidine tract and branchpoint site but an inactive
splice-donor site (ataagt). An ArG transition created a
functional donor splice site (gtaagt [the bold nt showing
the substitution]). The inserted cryptic exon contained
four in-frame PTCs that led to transcript instability.
The proa2(I) chain of type I procollagen contains an
amino-terminal propeptide that is substantially shorter
than the homologous region in the related ﬁbrillar col-
lagen genes, COL1A1 and COL3A1. The domain is
encoded by 6 exons in COL1A1 and COL1A2, but in
the latter, exon 2 contains only 11 nt and exon 3 is
truncated. The newly activated exon in P2 is upstream
of a portion of the intron that contains a sequence sim-
ilar to that seen in exon 2 of the COL1A1 gene and that
could be remnants of the ancestral gene in COL1A2 (ﬁg.
4).
The second abnormality detected in P2 was in the
product extending from exon 20 to exon 35 and ap-
peared to be identical, with PAGE (ﬁg. 2C), to the one
detected in P1 (ﬁg. 2A). Sequencing revealed 3′ trunca-
tion of exon 24 by 8 nt but, in this instance, caused by
a GrA transition at the 1 position of the intron 24
splice-donor site (IVS241GrA) in one allele that re-
sulted in use of the same cryptic donor site in exon 24
as seen in P1 (ﬁg. 3B [Allele 2]).
Homozygosity in P3.—A homozygous point mutation
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Figure 7 Order of intron removal between exons 23 and 26. The display of the data and the symbols used are identical to those in ﬁgure
5. A, Control Individual, Intron 23 was excised prior to intron 24 in most transcripts. P1, There was a major product from which intron 23
had been removed, but this product was signiﬁcantly more abundant than in the control individual at all time points, as a result of stagnation
of mutant transcripts prior to excision of intron 24 (ﬁg. 8). B, Control Individual, Intron 24 was excised prior to intron 25 in most transcripts.
P1, In a very small number of mutant transcripts, the removal of introns 24 and 25 followed the order that represented the dominant pathway
in the control—that is, removal of intron 24 before intron 25, and generation of a shorter-than-normal splice product due to use of the cryptic
exon 24 donor site that resulted in exon 24 truncation (undulated vertical line). C, Control Individual, There was hardly any signal representing
a product from which intron 25 had been excised prior to excision of intron 24. P1, The presence of the intron 24 splice donor site mutation
nearly abolished the ability to remove intron 24 prior to intron 25, and a new pathway was detected in which intron 25 was removed prior
to intron 24 (ﬁg. 8).
(c.3601GrT) in exon 50 of COL1A2 (ﬁg. 3C) resulted
in substitution of a nonsense codon for glutamic acid
(E1201X). Evidence that transcripts from those mutant
alleles were very unstable was obtained from detection
of only a normal sequence when cDNA from a control
individual and from P3 were mixed in equal proportion
before sequence template ampliﬁcation (not shown).
DNA from the brother of P3 was also sequenced, and
the same homozygous nucleotide substitution was
identiﬁed.
Determination of the Order of Intron Removal in P1
in Regions of Splice Site Mutations
Cells from P1 and from a control individual were in-
cubated with Actinomycin D to halt transcription, and
nuclear RNA was harvested after 0, 5, 10, 20, 40,
and 60 min and was reverse transcribed to cDNA.
Paired intron/exon primers were used to amplify dif-
ferent regions between exon 10 and intron 12 and
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Figure 8 Pathways of removal of introns 23, 24, and 25 from normal and mutant COL1A2 transcripts.Normal Allele, In the predominant
splice pathway, intron 23 removal preceded the removal of intron 24, and intron 25 was removed last. Mutant Allele 2, As in the normal
transcript, intron 23 was removed prior to removal of introns 24 and 25. The presence of the mutation signiﬁcantly diminished the ability to
remove intron 24 (via use of the cryptic exon 24–donor site) prior to removal of intron 25, resulting in prolonged presence of the precursor
splice intermediate (shown in ﬁg. 7) and in preferential removal of intron 25 prior to intron 24 (DOOS p change in order of splicing), a
pathway that was barely detectable in normal transcripts. Intron sizes are shown in the unspliced normal transcripts. An asterisk (*) indicates
the site of the mutation. The width of the arrows roughly reﬂects the amount of product derived from the respective branch of the pathway.
between exons 23 and 26 in the unspliced or partially
spliced precursor mRNA.
For the control individual, when primers were placed
in intron 10 and exon 12 (ﬁg. 5A), the majority of the
ampliﬁed product at 0 min contained intron 10 and in-
tron 11, and a less abundant product contained only
intron 10. There was some transfer of the label from the
large to the small fragment between 0 min and 10 min,
and the larger product diminished in intensity. These
ﬁndings are consistent with parallel pathways, a domi-
nant one in which removal of intron 10 precedes that
of intron 11 and a second in which removal of intron
11 occurs prior to that of intron 10 (ﬁg. 6).
In cells from P1 (IVS115GrA), the commitment of
transcripts from both alleles to the two pathways ap-
peared to be similar, but the ﬂow of themutant transcript
through the “intron-11-before-intron-10” pathway was
delayed (ﬁgs. 5 and 6), so that the product with both
introns accumulated. In this pathway, the removal of
intron 10 appeared to be dependent on the prior removal
of intron 11. When primers in exon 11 and intron 12
(ﬁg. 5B) or in exon 10 and intron 12 (ﬁg. 5C) were used,
it was apparent that intron 12 was very slowly removed,
relative to introns 10 and 11. Products obtained with
both primer sets showed a delay of mutant allele pro-
cessing that appeared to be resolved by use of a cryptic
donor site in intron 11. Once the cryptic donor site was
used and exon 11 was “redeﬁned” through addition of
60 nt derived from intron 11, the transcripts from the
mutant allele were processed at about the same rate as
the transcripts from the normal allele (ﬁg. 5B and 5C).
In the region from intron 23 to intron 25, the pre-
dominant splice pathway for control cells removed in-
trons 23, 24, and 25 in a processive fashion—intron 23
was removed before intron 24, and intron 25 was ex-
cised last (ﬁgs. 7A–7C and 8). In the nuclear cDNA from
P1, the use of primers annealing to exon 23 and intron
24 yielded a major product from which intron 23 had
been removed (ﬁgs. 7A and 8), a product that was sig-
niﬁcantly more abundant in P1 than in control cells at
all time points. The intron 24 splice donor site mutation
nearly abolished passage of mutant transcripts through
the “intron-24-before-intron-25” pathway, and, in con-
trast with the control individual, there appeared to be
a new pathway in which intron 25 was removed prior
to intron 24 (ﬁg. 7C). Once introns 23 and 25 were
excised from the mutant allele, the mutant intron 24
either was removed using a suboptimal cryptic donor
site (AGGTCCTG) at nt 8 of exon 24 or was retained
in a small proportion of mutant transcript (ﬁg. 8). The
intron 24 retention product was only detectable in very
low abundance in nuclear RNA and had not been seen
after ampliﬁcation of cDNA from total cellular RNA
(ﬁg. 2A). In a small number of transcripts from the mu-
tant allele, the removal of introns 24 and 25 followed
the order that represented the predominant pathway for
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Figure 9 Prediction of secondary structures of COL1A2 splice intermediates, as shown by mfold. A, Normal allele. The folded sequence
extends from exons 23 to 26 and contains introns 24 and 25. The intron 24–donor and –acceptor sites are juxtaposed and single stranded,
whereas the intron 25 sites are located some distance apart. B and C, IVS241GrC, The folded sequence contains exons 23–26 and intron
24. The site of the mutation at 1 is indicated by an oval attached to an arrow. The enlarged image (C) shows that the cryptic donor site at
nt 8 in exon 24, highlighted by a thick line, is juxtaposed to the single-stranded acceptor site of intron 24. Potential branchpoints are shown.
D and E, IVS241GrA, Folding results are shown, as in panels B and C. Intron sequences are framed by thin lines (A, B, and D). The
beginning of exon sequences is indicated by dashed arrows (A, B, and D). Donor and acceptor sites are indicated by solid arrows.
the control individual. That is, when primerswere placed
in exon 24 and intron 25, a shorter-than-normal splice
intermediate was seen, because of removal of intron 25
after intron 24 was removed via use of the cryptic exon
24 donor site (ﬁgs. 7B and 8).
Transcripts from the mutant allele used the cryptic
splice donor site in exon 24, even though its score (59.4)
was as low as that for the mutant constitutive intron 24
donor site (60.4)—on the basis of the Shapiro-Senapathy
calculation (Shapiro and Senapathy 1987)—presumably
because it contained the obligate GT dinucleotide.
RNA Secondary Structure Prediction and Potential
Effect on Splice Site Choice
As a ﬁrst step for examination of a role of mRNA
folding in directing use of splice sites, we studied the
region of the partially spliced COL1A2 pre-mRNA ex-
tending from exons 23 to 26. We used the mfold pro-
gram (see the “Material andMethods” section) to obtain
information on potential RNA secondary structures and
to determine if spatial arrangement might confer an ad-
vantage to a cryptic donor site.
We analyzed the RNA of the normal allele that con-
tained exons 23–26 and introns 24 and 25. In 3 of a
total of 35 folded structures, the donor and acceptor
sites of intron 24 remained single stranded and were
brought into juxtaposition, whereas the donor and
acceptor sites of intron 25 were located far apart (ﬁg.
9A). This structure might facilitate removal of intron 24
prior to excision of intron 25, consistent with the data
obtained experimentally (ﬁgs. 7 and 8). The donor and
acceptor sites were not juxtaposed in the remaining 32
structures.
We then analyzed the mRNAs that contained the mu-
tant sequences (IVS241GrC or IVS241GrA), using
the sequences of exons 23–26 and intron 24 (ﬁg. 9B and
9D). This splice intermediate is the major intermediate
that occurs with excision of intron 25 before use of the
cryptic donor site at nt 8 of exon 24 (ﬁgs. 7 and 8).
The presence of either donor site mutation resulted in
juxtaposition of the cryptic donor site and the single-
stranded intron 24 acceptor site in 1 of 13 folded struc-
tures (ﬁg. 9C and 9E). None of the other 12 placed the
sites in proximity. In 12 folded structures obtained with
the wild-type sequence (not shown), the cryptic donor
site was always engaged in basepairing interaction and
was not situated directly across from the acceptor site.
It is conceivable that the spatial proximity between cryp-
tic donor site and acceptor site, caused by either donor-
site mutation, promotes spliceosome access and cryptic
splice site use.
Discussion
Splice site mutations in the COL1A2 gene are usually
associated with an OI phenotype, the severity of
which depends on the location of the mutation. Those
near the 3′ end of the coding region of the triple helix
are often lethal, whereas those farther 5′ may have a
variable phenotype. For example, splice donor site mu-
tations in introns 9 (IVS91GrT), 12 (IVS121_19
del), 14 (IVS142TrC or rA), and 21 (IVS215GrA)
lead to exon skipping and moderate OI phenotypes,
whereas similar mutations in introns 30 (IVS301GrA),
32 (IVS321GrA), and 37 (IVS371GrT) lead to exon
skipping and lethal phenotypes (Byers and Cole 2002).
In the individuals we identiﬁed in this study, splice donor
site mutations result in unstable mRNAs, absence of
proa2(I) chain synthesis, and a moderately severe clas-
sic EDS phenotype with cardiac valvular involvement.
The phenotype is also seen with in-frame nonsense
mutations.
Prediction of the effects of splice site mutations on
the basis of sequence studies alone is not easy, and sev-
eral factors may inﬂuence the outcome. The “exon-def-
inition” model of splice site pairing suggests that mu-
tations in donor splice sites will result in exon skipping
or the activation of cryptic donor sites in the upstream
exon, whereas the “intron-deﬁnition” model predicts
that introns will be retained or cryptic donor sites in
the affected intron will be used (Robberson et al. 1990;
Berget 1995). These models assume that intron removal
follows only one of these pathways, so that complex or
mixed outcomes—for example, exon skipping in one
population and intron retention in another population
of mRNAs derived from the same mutant allele—would
not ensue.
In the analysis of splice site mutations in the complex
collagen genes, we found that mixed outcomes were
common and that determination of the order of intron
removal in the local domain helped to predict the prod-
ucts that resulted from splice site mutations (Schwarze
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et al. 1999; Takahara et al. 2002). In this fashion, mu-
tations in rapidly removed introns generally led to exon
skipping, whereas those in slowly removed introns led
to intron inclusion or use of cryptic sites. As noted by
Kessler and colleagues for the genes they studied (Kes-
sler et al. 1993), we found that some introns in collagen
genes appeared to participate in more than one pathway
and so were sometimes “fast” and sometimes “slow.”
“Fast” and “slow” in this context are deﬁned with re-
spect to relative rate of removal of adjacent introns and
also imply an “independent” or “dependent” character
of removal, in that “slow” intron removal reﬂects the
need for prior removal of “fast” introns.
In three of the six mutant alleles we identiﬁed in the
COL1A2 gene in this study, donor splice site altera-
tions led to mRNA instability. In two of the others, the
same nonsense codon resulted in mRNA instability,
whereas, in the sixth, the inclusion of a cryptic exon
that contained multiple termination codons had the
same effect. At ﬁrst glance, the splice donor mutations
(IVS115GrA, IVS241GrA, and IVS241GrC) are
similar to those that in other introns produce exon skip-
ping and a stable mRNA. In each current instance, how-
ever, the result is an unstable mRNA. We think this is
best explained by the order in which introns are nor-
mally removed.
In control cells, the removal of intron 24 follows re-
moval of intron 23, so that skipping of exon 24 would
not be possible in the presence of a donor site mutation
in intron 24. Following this prediction, in the cells that
contain the IVS24 mutations, intron 24 is retained for
an extended period, a suboptimal cryptic donor site that
creates a translational frameshift is used, and themRNA
is rapidly degraded.
Prediction of the outcome of the mutation in intron
11 is modiﬁed by the presence of a strong cryptic donor
site 61 nt downstream from the constitutive site. In this
domain, intron 11 is ordinarily removed in two path-
ways. In one pathway, intron 10 is removed prior to
intron 11; in the other, the order is reversed. In the
pathway in which intron 10 is removed quickly, exon
skipping is not available to resolve the splicing in the
presence of the intron 11 splice donor site mutation,
and so the use of a cryptic site follows. However, in the
pathway in which intron 11 would be removed rapidly,
exon skipping is expected, but, in all instances, the near
optimal cryptic donor site is used. One explanation for
this outcome appears to be a long delay in removal of
intron 11 that permits redirection of splicing for many
transcripts, such that intron 10 is removed rapidly. As
a consequence, it appears that the majority of tran-
scripts may be shuttled through the intron 10 “ﬁrst”
pathway, so that ultimately, the only choice of donor
sites in intron 11 is the near-optimal cryptic site. Such
redirection might reﬂect refolding of the nascent tran-
script to permit spliceosome access (see, e.g., Howe and
Ares [1997]).
Intron removal is thought to be largely cotranscrip-
tional, although evidence for this concept is not avail-
able for many genes (Neugebauer and Roth 1997; Gold-
strohm et al. 2001; Bentley 2002). Indeed, forCOL1A1,
at least one intron appears to be retained for a consid-
erable time following transcription (Johnson et al.
2000). Support for the idea that removal of introns is
not processive—that is, does not occur in the order of
transcription—is derived largely from the types of stud-
ies described here, albeit in smaller genes (Lang et al.
1985; Lang and Spritz 1987; Gudas et al. 1990; Kessler
et al. 1993). One concern about those studies and the
present study is that the substrate studied is not well
deﬁned. That is, is the population of mRNAs studied
simply a splicing “backwater” in which abnormally
spliced transcripts accumulate? At this point, there
are data neither to support nor to refute such a no-
tion. The idea that the order of intron removal can
predict, in part, the outcome of mutations at splice
sites is supported by our studies of several collagen
genes (COL1A1, COL1A2, COL3A1, and COL5A1)
(Schwarze et al. 1999; Takahara et al. 2002; U.S. un-
published data) and by those in the ﬁbrinogen a gene
(FGA) (Attanasio et al. 2003). The mechanisms by
which splice order is determined are not clear but could
include both folding of the nascent transcript (Balvay
et al. 1993; Howe and Ares 1997) and transcriptional
pausing (Keene et al. 1999), which can augment up-
stream splicing.
In one other patient with this type of EDS in whom
no proa2(I) chains could be detected, a splice donor site
mutation in intron 46 was identiﬁed (IVS462TrC).
This mutation permitted almost exclusive use of a cryp-
tic donor site 17 nt upstream in the exon (Nicholls et
al. 2001), but a very small amount of normal transcript
was detected. It is surprising that this patient had fea-
tures of OI, suggesting that abnormal protein chains
were made. Although the published studies did not iden-
tify an exon-skip product that might explain the phe-
notype, such a product could derive from a low-abun-
dance alternative pathway that was not appreciated.
This form of EDS and a moderately severe recessively
inherited form of OI (Nicholls et al. 1979) share ap-
parent similarities in their biochemical phenotype, in
that cells from affected individuals appear to synthesize
no proa2(I) chains. The mutations underlying the two
phenotypes are different. In this form of EDS, the
mRNA from the mutant alleles is unstable, and mRNA
degradation probably occurs in the nucleus or related
to a ﬁrst round of translation, so that no abnormal
protein is synthesized. In contrast, the moderately severe
OI type III phenotype results from homozygosity for a
short deletion and frameshift near the end of the coding
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region of the mRNA (Pihlajaniemi et al. 1984). The
mRNA is stable, but the proa2(I) polypeptide chain fails
to fold normally and is unstable and degraded. The basis
for OI in that patient is not clear but may result from
synthesis of a small number of abnormal molecules that
contain the defective chain. A similar phenotype is seen
in the oim/oimmouse with a virtually identicalmutation
(Chipman et al. 1993). There is no follow-up infor-
mation published about the child with this form of OI,
so we cannot exclude the possibility that he has a val-
vular phenotype. The oim/oim mouse does not appear
to have a valvular phenotype.
The phenotype of these individuals with “pure”
COL1A2 nulls includes valvular heart disease. Two of
the four adults described here had involvement of both
the aortic and mitral valves (P1 and P3), and in the
other two either the aortic valve (brother of P3) or the
mitral valve (P2) was involved. All four individuals un-
derwent valve replacement surgery, as did the ﬁfth pa-
tient, with aortic valve involvement, described by Sasaki
et al. (1987). The sixth known patient is a child and so
is still potentially at risk (Nicholls et al. 2001). These
ﬁndings suggest that the a2(I) chain is important for
functions in soft tissues but that bone can form in a
normal or near-normal fashion in individuals whose
cells make no a2(I) chains. This is an unexpected ﬁnding
of the study of these mutations, one that warrants more
detailed investigation into the function of the chain in
different tissues.
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